


Attorney Docket No. 0/98414 US

In the Claims

1. (Previously Presented) A pharmaceutical composition having ER α agonist activity and having ER β antagonist activity, comprising:

a steroid compound satisfying the following structural formula:



formula I

wherein:

one of X and Y is OH, the other being H;


R₃ is H or COR'₃, with R'₃ being alkyl or aryl;

R₇, R₁₆, and R₁₇ each independently are H, alkyl, cycloalkyl, alkenyl, alkynyl or aryl; R₁₁ is a hydrocarbon group, which may be linear or branched, comprising one single linear chain having a length of from 5 to 9 carbon atoms as the longest chain on carbon atom no. 11 of the steroid skeleton, wherein said chain may be saturated or unsaturated, and

a pharmaceutical acceptable auxiliary.

Attorney Docket No. O/98414 US

2. (Currently Amended) The pharmaceutical composition according to claim 1, wherein R_{11} is selected from the following group of side-chain structures selected from the group consisting of



I think the structures should be as above (see Table B). All invention cpds. have a chain of 5 carbon atoms. See also my amendments to Claim 14.

Attorney Docket No. 0/98414 US

3. (Previously Presented) The pharmaceutical composition according to claim 1, wherein the longest chain in R_{11} comprises 5-7 carbon atoms.

4. (Previously Presented) The pharmaceutical composition according to claim 3, wherein the longest chain in R_{11} comprises 5 carbon atoms.

5. (Canceled).

6. (Canceled).


7. (Previously Presented) A method for treating estrogen deficiency disorders, comprising:

administering to a patient afflicted with an estrogen deficiency disorder an effective amount of the pharmaceutical composition of claim 1.

8. (Previously Presented) A method of inducing $ER\alpha$ agonist activity and $ER\beta$ antagonist activity in a patient in need thereof, comprising:

administering an effective amount of a steroid compound satisfying the following structural formula:

Attorney Docket No. 0/98414 US



formula I

wherein:

one of X and Y is OH, the other being H;

R_3 is H or COR'_3 , with R'_3 being alkyl or aryl;

R_7 , R_{16} , and R_{17} each independently are H, alkyl, cycloalkyl, alkenyl, alkynyl or aryl;

R_{11} is a hydrocarbon group, which may be linear or branched, comprising one single linear chain having a length of from 5 to 9 carbon atoms as the longest chain on carbon atom no. 11 of the steroid skeleton, wherein said chain may be saturated or unsaturated.

9. (Canceled).


10. (Canceled).

11. (Canceled).

12. (Canceled).

Attorney Docket No. O/98414 US

13. (New) A steroid compound having ER α agonist activity and having ER β antagonist activity and satisfying the following structural formula:



formula I

wherein:


one of X and Y is OH, the other being H;

R₃ is H or COR', with R' being alkyl or aryl;

R₇, R₁₆, and R₁₇ each independently are H, alkyl, cycloalkyl, alkenyl, alkynyl or aryl; R₁₁ is a hydrocarbon group, which may be linear or branched, comprising one single linear chain having a length of from 5 to 9 carbon atoms as the longest chain on carbon atom no. 11 of the steroid skeleton, wherein said chain may be saturated or unsaturated.

14. (New) The steroid compound according to claim 13, wherein R₁₁ is selected from the following group of side-chain structures selected from the group consisting of

Attorney Docket No. 0/98414 US



Note the changes I made to Claim 14, as I previously indicated.

15. (New) The steroid compound according to claim 13, wherein the longest chain in R₁₁ comprises 5-7 carbon atoms.

16. (New) The steroid compound according to claim 15, wherein the longest chain in R₁₁ comprises 5 carbon atoms.